Categories
Prostate cancer

Optimizing anti-androgen treatment use among men with pathologic lymph-node positive prostate cancer treated with radical prostatectomy: the importance of postoperative PSA kinetics

  • Daneshmand S, Quek ML, Stein JP, Lieskovsky G, Cai J, Pinski J, et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol. 2004;172:2252–5.

    Article 

    Google Scholar
     

  • Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol. 2007;178:864–70. discussion 870-861.

    Article 

    Google Scholar
     

  • Diaz M, Peabody JO, Kapoor V, Sammon J, Rogers CG, Stricker H, et al. Oncologic outcomes at 10 years following robotic radical prostatectomy. Eur Urol. 2015;67:1168–76.

    Article 

    Google Scholar
     

  • Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781–8.

    CAS 
    Article 

    Google Scholar
     

  • Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7:472–9.

    CAS 
    Article 

    Google Scholar
     

  • Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–7.

    CAS 
    Article 

    Google Scholar
     

  • Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K. Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol. 2009;27:100–5.

    Article 

    Google Scholar
     

  • Touijer KA, Mazzola CR, Sjoberg DD, Scardino PT, Eastham JA. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol. 2014;65:20–25.

    Article 

    Google Scholar
     

  • Kim DK, Koo KC, Abdel Raheem A, Kim KH, Chung BH, Choi YD, et al. Single positive lymph node prostate cancer can be treated surgically without recurrence. PLoS One. 2016;11:e0152391.

    Article 

    Google Scholar
     

  • Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N, et al. Predicting survival of patients with node-positive prostate cancer following multimodal treatment. Eur Urol. 2014;65:554–62.

    Article 

    Google Scholar
     

  • VanderWeele DJ, Finney R, Katayama K, Gillard M, Paner G, Imoto S, et al. Genomic heterogeneity within individual prostate cancer foci impacts predictive biomarkers of targeted therapy. Eur Urol Focus. 2019;5:416–24.

    Article 

    Google Scholar
     

  • Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238–44.

    CAS 
    Article 

    Google Scholar
     

  • Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–56.

    CAS 
    Article 

    Google Scholar
     

  • Abdollah F, Sammon JD, Reznor G, Sood A, Schmid M, Klett DE, et al. Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged >/=66 years. Eur J Surg Oncol. 2015;41:1529–39.

    CAS 
    Article 

    Google Scholar
     

  • Schmid M, Sammon JD, Reznor G, Kapoor V, Speed JM, Abdollah FA, et al. Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events. BJU Int. 2016;118:221–9.

    CAS 
    Article 

    Google Scholar
     

  • Menon M, Tewari A, Peabody J, Team VIP. Vattikuti Institute prostatectomy: technique. J Urol. 2003;169:2289–92.

    Article 

    Google Scholar
     

  • Ghani KR, Trinh QD, Menon M. Vattikuti Institute Prostatectomy-Technique in 2012. J Endourol / Endourological Soc. 2012;26:1558–65.

    Article 

    Google Scholar
     

  • Sood A, Jeong W, Peabody JO, Hemal AK, Menon M. Robot-assisted radical prostatectomy: inching toward gold standard. Urol Clin North Am. 2014;41:473–84.

    Article 

    Google Scholar
     

  • Mattei A, Fuechsel FG, Bhatta Dhar N, Warncke SH, Thalmann GN, Krause T, et al. The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol. 2008;53:118–25.

    Article 

    Google Scholar
     

  • Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol. 2013;190:441–9.

    Article 

    Google Scholar
     

  • Gharzai LA, Jiang R, Wallington D, Jones G, Birer S, Jairath N, et al. Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. Lancet Oncol. 2021;22:402–10.

    Article 

    Google Scholar
     

  • Segal MR. Regression trees for censored data. Biometrics. 1988;44:35–47.

    Article 

    Google Scholar
     

  • Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010;5:1315–6.

    Article 

    Google Scholar
     

  • Krasnova A, Epstein M, Marchese M, Dickerman BA, Cole AP, Lipsitz SR, et al. Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2020;23:410–8.

    CAS 
    Article 

    Google Scholar
     

  • Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl J Med. 2008;358:1250–61.

    CAS 
    Article 

    Google Scholar
     

  • van Andel G, Kurth KH. The impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancer. Eur Urol. 2003;44:209–14.

    Article 

    Google Scholar
     

  • Kang JJ, Reiter RE, Steinberg ML, King CR. Ultrasensitive prostate specific antigen after prostatectomy reliably identifies patients requiring postoperative radiotherapy. J Urol. 2015;193:1532–8.

    Article 

    Google Scholar
     

  • Grivas N, de Bruin D, Barwari K, van Muilekom E, Tillier C, van Leeuwen PJ, et al. Ultrasensitive prostate-specific antigen level as a predictor of biochemical progression after robot-assisted radical prostatectomy: Towards risk adapted follow-up. J Clin Lab Anal. 2019;33:e22693.

    Article 

    Google Scholar
     

  • Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243–62.

    CAS 
    Article 

    Google Scholar
     

  • Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79:263–82.

    CAS 
    Article 

    Google Scholar
     

  • Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N, et al. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J Clin Oncol. 2014;32:3939–47.

    Article 

    Google Scholar
     

  • Touijer KA, Karnes RJ, Passoni N, Sjoberg DD, Assel M, Fossati N, et al. Survival outcomes of men with lymph node-positive prostate cancer after radical prostatectomy: a comparative analysis of different postoperative management strategies. Eur Urol. 2018;73:890–6.

    Article 

    Google Scholar
     

  • Tilki D, Chen MH, Wu J, Huland H, Graefen M, Wiegel T, et al. Adjuvant versus early salvage radiation therapy for men at high risk for recurrence following radical prostatectomy for prostate cancer and the risk of death. J Clin Oncol. 2021;39:2284–93.

    CAS 
    Article 

    Google Scholar
     

  • Wang X, Kattan MW. Cohort studies: design, analysis, and reporting. Chest. 2020;158(1S):S72–S78.

    Article 

    Google Scholar
     

  • Hoffmann MA, Buchholz HG, Wieler HJ, Miederer M, Rosar F, Fischer N et al. PSA and PSA kinetics thresholds for the presence of (68)Ga-PSMA-11 PET/CT-detectable lesions in patients with biochemical recurrent prostate cancer. Cancers (Basel). 2020;12:398.

  • Bhargava P, Ravizzini G, Chapin BF, Kundra V. Imaging Biochemical Recurrence After Prostatectomy: Where Are We Headed? AJR Am J Roentgenol. 2020;214:1248–58.

    Article 

    Google Scholar
     

  • Daly T. Evolution of definitive external beam radiation therapy in the treatment of prostate cancer. World J Urol. 2020;38:565–91.

    Article 

    Google Scholar
     

  • Magnan S, Zarychanski R, Pilote L, Bernier L, Shemilt M, Vigneault E, et al. Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. JAMA Oncol. 2015;1:1261–9.

    Article 

    Google Scholar
     

  • Leave a Reply